We expect to produce REOLYSIN(R) for our clinical trial program throughout 2008. We believe we will complete our 100-litre scale up studies and will continue our examination of a lyophilization (freeze drying) process for REOLYSIN(R).
We continue to estimate, based on our expected activity for 2008 that
our average monthly cash usage will be $1,660,000 per month (see "Liquidity
and Capital Resources").
Recent 2008 Progress
Clinical Trials - Positive Interim Results
In April, we announced positive interim results and completion of the dose escalation portion of our U.K. combination REOLYSIN(R) and carboplatin/paclitaxel trial. Four of the first eight patients treated in the study to date have a diagnosis of carcinoma of the head and neck. All three head and neck patients evaluated to date have had excellent clinical and radiological responses without appreciable toxicity. Preliminary assessment after recruitment of the first two cohorts has suggested that patients with head and neck carcinomas represent a group of patients for whom the combination of carboplatin/paclitaxel and REOLYSIN(R) may prove effective.
In the first cohort, the patient with head and neck cancer received 8
cycles of treatment (the maximum allowed) and achieved a clinical complete
response. In the second cohort, the two patients with head and neck cancers
with widespread disseminated disease have each received seven cycles of
treatment to date and both have achieved significant partial responses. Two
of the three patients, including the patient with the clinical complete
response, had previously received cisplatin/5-FU treatment and all three
|SOURCE Oncolytics Biotech Inc.|
Copyright©2008 PR Newswire.
All rights reserved